金信諾(300252.SZ):張田解除質押1股及補充質押230萬股
格隆匯5月22日丨金信諾(300252.SZ)公佈,公司近日接到公司股東張田的函告,獲悉張田將前次質押給中信證券的公司股票部分購回並補充質押,解除質押1股,補充質押230萬股。
控股股東及其一致行動人未來半年內到期的質押股份累計數量為4139.9998萬股,佔控股股東及其一致行動人直接和間接持股的比例為20.50%,佔公司總股本的7.17%;未來一年內到期(含半年內到期)的質押股份累計數量為111,759,998股,佔控股股東及其一致行動人直接和間接持股的比例為55.35%,佔公司總股本的19.34%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.